866398-16-5

Upstream product

• 358-23-6 trifluoromethylsulfonic anhydride 
• 60526-69-4 4-(1,1-dimethylheptyl)-2,6-dimethoxyphenol 
• 91-10-1 1,3-dimethoxy-2-hydroxy-benzene 
• 628-44-4 2-methyl-2-octanol 

Downstream Products

• 87613-50-1 3-(1,1-dimethylheptyl)-5-methoxyphenol 
• 181764-33-0 1-bromo-4-(1,1-dimethylheptyl)-2-methoxybenzene 
• 866398-21-2 1-(1,1-dimethylheptyl)-3-methoxybenzene 
• 83002-04-4 CP 55,940 
• 866398-07-4 (7R,8R)-7-[4-(1,1-dimethylheptyl)-2-methoxyphenyl]-8-(2-[1,3]dioxolan-2-ylethyl)-1,4-dioxaspiro[4,5]decane 
• 866398-09-6 3-{(7R,8R)-7-[4-(1,1-dimethylheptyl)-2-methoxyphenyl]-1,4-dioxaspiro[4,5]dec-8-yl}propan-1-ol 
• 866398-05-2 (1R,4R,5R,8S)-4-[4-(1,1-dimethylheptyl)-2-methoxyphenyl]-8-methoxymethoxybicyclo[3.3.1]non-3-en-2-one 
• 866398-11-0 (1R,3R,4R)-3-[4-(1,1-dimethylheptyl)-2-methoxyphenyl]-4-(3-hydroxypropyl)cyclohexanol 
• 866398-19-8 trifluoromethanesulfonic acid 3-(1,1-dimethylheptyl)-5-methoxyphenyl ester 
• 60526-81-0 1-(1',1'-dimethylheptyl)-3,5-dimethoxybenzene 

Relevant academic research and scientific papers

METHODS AND COMPOSITIONS RELATING TO ULTRAPURE 5-(1,1-DIMETHYLHEPTYL)-RESORCINOL

The invention provides methods and compositions relating to an ultrapure formulation of 5-(1,1-dimethylheptyl)-resorcinol (ultrapure DMHR). The invention features methods for making ultrapure DMHR, including methods that minimize the production of unwanted side products (e.g., the production of homologous alkyl-chain impurities). The invention also features methods of making cannabinoids, such as (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyl-2-octanyl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene-9-carboxylic acid (ajulemic acid), using ultrapure DMHR, including methods that minimize the production of unwanted side products (e.g., the production of homologous alkyl-chain impurities) in the resulting cannabinoid preparation.

Expedient synthesis of potent cannabinoid receptor agonist (-)-CP55,940

(Chemical Equation Presented) A stereocontrolled synthesis of (-)-CP55,940, a potent cannabinoid receptor agonist, has been attained using a novel aldolization/retroaldolization interconversion strategy, in which a temporarily generated chiral aldol motif plays essential roles.